GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions. GSK will pay $1 billion upfront and up to $400 million in success-based milestone payments. "In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Jiangsu Hengrui Pharmaceuticals Co, Ltd," the group said.
Related Keywords
London , City Of , United Kingdom , Aiolos Bio , Pablo Mayo Cerqueiro , Jason Neely , Jiangsu Hengrui Pharmaceuticals Co Ltd , , Inflammatory Conditions , Iopharmaceutical Company , Milestone Payments ,
comparemela.com © 2020. All Rights Reserved.